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Abstract
Introduction Magnetic resonance (MR) methods are non-
invasive techniques to provide detailed, multi-parametric
information on human anatomy, function and metabolism.
Sensitivity, specificity, spatial and temporal resolution may,
however, vary depending on hardware (e.g., field strength,
gradient strength and speed) and software (optimised mea-
surement protocols and parameters for the various tech-
niques). Furthermore, multi-modality imaging may enhance
specificity to better characterise complex disease patterns.
Objective Positron emission tomography (PET) is an interest-
ing, largely complementary modality, which might be com-
bined with MR. Despite obvious advantages, combining these
rather different physical methods may also pose challenging
problems. At this early stage, it seems that PET quality may be
preserved in the magnetic field and, if an adequate detector
material is used for the PET, MR sensitivity should not be
significantly degraded. Again, this may vary for the different
MR techniques, whereby functional and metabolic MR is
more susceptible than standard anatomical imaging.
Discussion Here we provide a short introduction to MR
basics and MR techniques, also discussing advantages,
artefacts and problems when MR hardware and PET
detectors are combined. In addition to references for more
detailed descriptions of MR fundamentals and applications,
we provide an early outlook on this novel and exciting
multi-modality approach to PET/MR.
Keywords Magnetic resonance . Imaging . Spectroscopy .
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Introduction
Since magnetic resonance imaging (MRI) entered the
clinical arena in the early 1980s, MRI has experienced
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dramatic advances associated with an increasing number of
clinical applications that, in turn, are driving further
technical developments. Shortly after its introduction,
MRI became one of the most important diagnostic imaging
modalities and continues this role today. This success is due
to the inherent characteristics of anatomical MRI, featuring
excellent soft tissue contrasts that are based on multiple
contrast parameters, the ability to image in oblique
orientations and the capability to provide two-dimensional
(2D) as well as 3D data. MRI is considered a non-invasive
diagnostic imaging modality that generates cross-sectional
images of the human body without the use of ionising
radiation. The diagnostic importance of MRI is impressive-
ly reflected by an ever growing number of MRI scanner
installations. Informal market research studies suggest that,
today (2008), about 20,000–24,000 MRI systems are
installed and operational worldwide. These studies also
indicate that about 60–80 million MRI examinations are
being performed each year.
As the MR signal depends on a variety of physical tissue
parameters, MRI may also provide a broad range of
functional information on diffusion, perfusion, flow rates,
temperature, magnetic susceptibility, etc. beyond displaying
morphologic and structural information. Owing to this
spectrum of information, the clinical applications of MRI
encompass neurological, psychiatric, abdominal, cardiac,
vascular as well as musculoskeletal applications, covering
the entire human body. Furthermore, metabolic changes in
and around tumours, degenerative brain diseases and
accompanying the metabolic syndrome may be visualised
using MR spectroscopy (1H, 13C, 31P) or spectroscopic
imaging (1H, 31P). With the advent of whole-body MR
imaging technologies [1], whole-body tumour staging and
screening for metastasis has become a viable option today
[2–4].
In the context of combined PET and MR imaging, it is
important to understand the underlying principles and
limitations of both imaging modalities. To provide a
basic understanding of MR technology, we shall describe
the most important MRI hardware components, their
interaction with the human body and some of the most
common measurement techniques and parameters that
may be varied by the user to obtain the diagnostic
information of choice.
We conclude by summarising current knowledge on
advantages and challenges in combining the two imaging
modalities.
MR hardware
The useable field-of-view (FOV) of an MRI system, in
general, is defined by three hardware groups and their
related parameters: (1) the main magnet with its homoge-
neity over the imaging volume; (2) the gradient system with
its linearity over the imaging volume; and (3) the radio-
frequency (RF) system with its signal homogeneity and
signal sensitivity over the active imaging volume (Fig. 1).
Typically, a superconducting magnet provides the high
magnetic field strength for producing a strong tissue
magnetization and, thus, a basis for high signal-to-noise
ratios (SNR). The gradient system plays an important role
in signal localization: it must be strong enough to switch
the highest possible gradient amplitudes in the shortest
possible time to enable rapid data acquisition. Also, it may
help to compensate for geometric distortions or suscepti-
bility artefacts. The RF system is charged with receiving the
weak MR signal with the very minimum of loss. State-of-
the-art magnetic resonance spectroscopy (MRS) and MRI
impose very specific demands on these system components
of system hardware. Phased-array surface RF coil technol-
ogy, for example, provides means for shorter acquisition
times and enhanced data acquisition flexibility through the
use of parallel imaging strategies combined with whole-
body surface RF coil coverage of the patient [5].
Main magnet—homogeneous static magnetic field
The magnet of a whole-body MR scanner should have a
high main magnetic field strength, B0, to provide sufficient
equilibrium magnetization and therefore a high potential
SNR for good image quality. MR systems with field
strengths above 1.0 T, or better yet 1.5 T, are currently
assumed as the clinical standard and are increasingly being
supplemented with 3 T systems in clinical use. Beyond
clinical application, a limited but increasing number of 7 T,
or even higher field whole-body MR systems have been
installed for research investigation in human high-field MR.
The homogeneity of the basic magnetic field over the
examination volume should be as high as possible to ensure
low image distortion and high signal uniformity. Also, the
homogenous examination volume should be as large as
possible. A cylindrical main magnet with the homogeneous
volume centred on the central axis fulfils all these require-
ments and, therefore, represents the most frequent magnet
design today (Fig. 1).
Gradient system—strong, fast and linear (orthogonal)
gradient fields
Three orthogonal gradient fields (Gx, Gy and Gz) are needed
for spatial localisation. For performing fast MR imaging,
two parameters of the gradient system are critical: a fast
gradient slew rate [given in (mT/m/ms)] combined with a
high gradient amplitude [given in (mT/m)] are the prereq-
uisites for short repetition (TR) and echo times (TE) and,
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therefore, for coverage of a large examination volume in the
shortest time possible. This can be seen as a fundamental
prerequisite for clinically acceptable examination times and
for covering large volumes in multi-station or continuously
moving table whole-body MRI applications. Ultrafast
gradients are also essential in functional (echo-planar)
MRI. Fast switching of high-amplitude gradients may,
however, also increase the risk of peripheral nerve
stimulations [6]. A high degree of gradient linearity over
a large volume is required by the gradient system to keep
image distortion in and around the image volume to a
minimum. These gradient system requirements can be best
realized with a cylindrical design to conform to the magnet
geometry (Fig. 1).
RF system—homogeneous spin excitation across the body
The radiofrequency (RF) system, in general, consists of a
RF transmit coil installed within the MR housing for
selective RF excitation of the spins as well as a RF receiver
coil system for receiving the weak RF signals leaving the
patient. RF excitation of the tissue volume of interest
should be as homogeneous as possible. Here, it is important
that the RF signal strength for tissue excitation (indicated
by the flip angle) remains consistent across the image.
Large cylindrical volume transmit RF coils with a conduc-
tor geometry similar to a birdcage and fitted within the
cylindrical magnet tunnel are typically used (Fig. 1).
On the signal receive side, homogenous RF signal
reception over as large an examination volume as possible
is desired. However, homogeneity is less important in
comparison to signal sensitivity, as inhomogeneous recep-
tion intensity only affects the brightness distribution over
the volume, but not the underlying image contrast. Here, as
in the transmit case, a whole-body RF coil fitted perma-
nently within the magnet would be advantageous. However,
the use of large volume coils limits signal reception and
achievable SNR. Hence, various concepts for local RF
surface coils have been proposed. Surface RF coils are
placed directly over the examination region and receive
signals from the immediate vicinity of the coil. The
potentially achievable SNR with these coils is much higher
than with a volume transmit coil. At the same time, surface
coils have a severely restricted sensitivity range. Several
coil elements of this type are required to cover larger
anatomical regions; they can be combined as phased-array
surface coils. Phased-array coils allow optimization of the
SNR while extending the region for signal reception
(Fig. 2). For imaging of large regions—up to whole-body
MR imaging applications—a full set of dedicated local
phased-array RF surface coils can be combined on state-of-
the-art 1.5 and 3 T MRI systems. A prerequisite for
exploring the advantages inherent to this type of coil
technology is a large number of RF receivers to which the
coil elements can be connected either individually or in
groups. This is also a basic prerequisite for the use of
parallel imaging techniques where spatial-encoding infor-
mation of individual RF coil elements can be used to speed
up image acquisition.
MR protocol parameters—timing of RF and gradient
pulses determines contrast and location
Even the best performing MR hardware mandates MR
sequences optimized for particular applications. In this
(c) RF transmit coil: B1
(b) gradient coils: Gx, Gy, Gz
surface RF receive coilsisocenter (imaging volume)
(a) magnet coil: Bo
(c) RF transmit coil: B1
(b) gradient coils: Gx, Gy, Gz
(a) magnet coil: Bo
Fig. 1 Scheme of a MRI sys-
tem. (a) magnet coil to produce
the homogeneous static magnet-
ic field (B0) for spin alignment;
(b) gradient coils to produce the
time-varying gradient fields (Gx,
Gy and Gz) for spatial encoding
of the MR signals, and (c)
transmitter radiofrequency (RF)
coil to generate an RF field (B1)
for spin excitation. The MR
signal response from the excited
spins within the subject is
detected by a set of receive-only
surface RF coils placed above
and below the image volume.
Note, the transmit RF coil is
optimized for B1 homogeneity
whereas the surface RF coils are
optimized for SNR
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context, “sequence” refers to a combination of well-defined
RF pulses and gradient switching schemes. The specifics of
such a pulse sequence determine not only the MR modality
(e.g., imaging or spectroscopy), but also contrast and
resolution. The combination of a pulse sequence and a
particular parameter set (TR, TE, flip angle, matrix size,
field-of-view, etc.) defines a protocol. Figure 3 shows two
representative examples for MR sequences.
Short RF pulses of a few milliseconds duration are
required to excite the nuclear spins. This energy is
deposited in the sample and is then irradiated back to a
signal-receiving coil. A considerable share of this energy is
dissipated into thermal energy and is referred to as the
specific absorption rate (SAR). As this process causes
tissue warming, which may be harmful to the patient, SAR
limits are constantly controlled throughout an MR scan to
ensure compliance with international MR safety guidelines.
As indicated by the term “resonance”, spin ensembles will
absorb this RF energy effectively only if the transmission
frequency is equal to the Larmor frequency of the spins,
which scales linearly with the magnetic field strength. For
hydrogen nuclei (1H), this frequency increases from
64 MHz at 1.5 T to 128 MHz at 3 T. It is possible to
limit excitation to certain parts of the subject through
spatial variation of the magnetic field (via gradients) during
RF excitation, thus allowing selection of a volume of

















Fig. 3 MR sequence schemes
indicating the temporal se-
quence of RF pulses, gradients
and signal acquisition. The
spectroscopy sequence (a) con-
sists of a voxel-selection part
with three orthogonal slice
selections, water suppression
and final signal acquisition. The
2D imaging sequence (b)
includes initial slice-selective
RF excitation, an in-plane phase
encoding gradient (before signal
acquisition) and a frequency-








Fig. 2 Schematic representation of radiofrequency (RF) surface coil
technology in top view (a) and side view (b). Whole-body coverage of
the patient with a full complement of separate RF surface coils in
combination with motorized table movement permits whole-body MR
imaging applications with relatively high SNR. (c) a close-up of a
typical RF receiver single-loop coil element made from copper
conductors (1), ceramic capacitors (2), and coaxial cables (3). Multiple
coil elements form a multi-channel RF array coil. For MR signal
reception, in a combined MR-PET imaging setup, the RF receiver coils
will physically lie between the signal emitting patient and the PET
detectors, which potentially could impact the attenuation correction as
well as the resulting PET image quality
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Image contrast, i.e., the relative signal appearance of
certain tissues, is determined by tissue properties, sequence
type, and sequence parameters (see Fig. 4). Several
relaxation constants are used to describe decay and
recovery of the MR signal. Most importantly, the longitu-
dinal (or spin-lattice) relaxation time, T1, indicates the rate
at which the magnetization builds up after an excitation
pulse. Tissues with longer T1 appear hypointense on T1-
weighted (T1w) images. The transverse (or spin–spin)
relaxation times, T2 and T2*, refer to the rate of signal
decay after RF excitation. Tissues with longer T2 appear
hyperintense on T2w images. The two most important
MR parameters governing nearly every MR sequence are
echo time (TE) and repetition time (TR). While TE refers
to the time between RF excitation and signal acquisition,
TR indicates the time between subsequent RF excitations.
In combination, TE and TR critically determine the rela-
tive contrast weighting of the different tissues. Protocols
with short TR and TE will yield T1w images; long TR
and TE will yield T2w images. Combining long TR and short
TE leads to proton-density-weighted images, where image
signal is solely determined by voxel hydrogen content.
Acquisitions with short TR and long TE are characterized
by very low MR signal strength and are thus not commonly
used. The differentiation between T2w and T2*w is primarily
determined by the selection of signal refocusing via RF pulses
or gradient pulses, as images will generally show T2w
whenever 180° RF pulses (“spin echoes”) are used, but will
be T2*w when gradient echoes are formed.
In the case of MR spectroscopy, we are interested in
metabolite concentrations rather than water content. Hy-
drogen nuclei bound to metabolites exhibit slightly different
Larmor (resonance) frequencies (“chemical shift”) depend-
ing on the density of the local chemical environment and,
hence, on the density of the electrons. The differences in
electron density result in variable shielding of the hydrogen
nuclei and, consequently, lead to different resonance
frequencies. It is possible to apply a specially designed
a b c d
e f g h
Fig. 4 Choice of multi-parameter soft tissue contrasts available with
MRI. Repeated MR imaging of an axial cross-section through the
brain of a normal volunteer demonstrates how the soft tissue contrast
can be varied simply through the appropriate choice of imaging
sequences and corresponding sequence parameters. (a–d) show the
basic MRI contrasts: (a) T1w, (b) T1w with contrast agent, (c) T2w,
(d) proton-density-weighted. (e) and (f) show FLAIR and inversion
recovery sequences, respectively. (g) Diffusion-weighted image (DWI)
of the brain, and (h) provides a maximum-intensity projection (MIP)
of a non-contrast-enhanced 3D time-of-flight (TOF) angiogram of the
intracranial vessels
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RF pulse to suppress the water signal without altering the
metabolite signals. This is required as the mobile water
content in human tissue is typically about 50 mol, resulting
in a significant water peak, which would mask metabolite
peaks detectable by 1H-MRS (sensitivity in the mM range).
Fourier transformation of the acquired MR signal then
provides the full spectrum of metabolites in the specified
voxel. The duration for single-voxel MRS is just a few
minutes, and the spatial resolution is 1 cm3 or less. In some
sequences, referred to as chemical shift imaging (CSI),
additional gradients are applied prior to signal acquisition
to introduce spatial encoding within the preselected
volume, enabling acquisition of spectrums from multiple
individual voxels to provide insight into the spatial
distribution of the spectroscopic information. This method
allows performing MRS with a spatial resolution of 0.1 cm3
or less [7], which is, however, associated with a significant
increase in measurement time up to 1 h or more.
Imaging sequences require additional gradients to intro-
duce spatial encoding (Fig. 3; right). Depending on whether
the gradients are applied before or during signal acquisition,
they are referred to as phase or readout gradients, respec-
tively. MR signals for imaging sequences are acquired within
k-space, which may be regarded as a mathematical model for
spin-gradient interactions. The final image is reconstructed
after 2D Fourier transformation of the k-space signal. In
standard imaging sequences, a single line of k-space is
acquired after each RF excitation, i.e., for N image lines (the
final image matrix has N pixels along one side), the sequence
has to be repeated N times, leading to image acquisition
times of up to several minutes. In current ultrafast imaging
techniques like echo-planar imaging (EPI) or Turbo Spin
Echo (TSE), however, multiple k-space lines or even the




Anatomical imaging by MRI and CT is the clinical standard
for all stages in the management of tumour patients, e.g.,
detection, characterization and staging of the lesion, control
of therapeutic response and determination of recurrence.
However, it is well known that imaging of the anatomical
structure alone suffers from many shortcomings. The
evaluation of macroscopic changes in lesions and tissues
can lead to a false assessment of the pathologic processes
and their progression on the cellular and molecular levels.
Furthermore, macroscopic abnormalities commonly are
nonspecific and reveal no information about physiological
and biological processes.
Functional MRI
This technique uses ultrafast imaging methods, mainly
echo-planar imaging (EPI), to collect functional informa-
tion on blood oxygenation or flow changes [BOLD
functional MRI (fMRI)], perfusion or diffusion. fMRI
based on the blood oxygen level-dependent (BOLD) effect
has been increasingly used to investigate brain function
since its introduction in 1990 [8]. It shows a wide field of
applications ranging from the investigation of basal and
higher brain functions in healthy subjects and animals to
pharmacological studies and the preoperative localization of
eloquent cortical areas in patients. However, BOLD fMRI
assesses changes in the deoxyhemoglobin level, which is
associated with hemodynamic response due to changes in
neuronal activity. Stimulation of a particular brain area via a
defined paradigm leads to a local increase in cerebral blood
flow and volume and to a decrease of deoxyhemoglobin
content in the capillary bed and the venous-draining
vessels. Due to the paramagnetic nature of deoxyhemoglo-
bin, tissue T2* relaxation time is increased, and subse-
quently an increased signal intensity on T2*w images is
also observed. In order to observe the BOLD signal change,
a T2*w sequence is needed, typically an echo-planar
imaging sequence. MR protocols with a TE approximately
equal to T2* result in maximum BOLD sensitivity upon
brain activation.
Compared to functional PET studies, BOLD fMRI
experiments show similar spatial resolution and superior
temporal resolution. Electrophysiological methods such as
EEG and MEG offer better temporal resolution, but EEG
has less spatial accuracy and MEG is less available.
However, when performing BOLD fMRI, one has to keep
in mind the potential confounds, which can occur through
drug or disease-induced modulation of physiological events
responsible for the generation of the BOLD signal. BOLD
fMRI studies are strongly recommended for the preopera-
tive diagnostics of brain tumour patients to delineate
functionally important neuronal tissue, which should be
preserved during treatment, as well as to obtain information
on tumour-induced brain plasticity [10, 11].
Perfusion imaging
This technique is used to investigate differences in the
blood supply of lesions and healthy tissue. In principle,
noninvasive arterial spin labelling (ASL) can be used to
magnetically tag inflowing blood in order to get a direct
measurement of organ perfusion [12]. ASL suffers,
however, from intrinsically low SNR, and, thus, most
applications employ exogenous contrast agents. Dynamic
contrast-enhanced MRI (DCE-MRI) techniques require the
acquisition of images before, during, and after intravenous
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administration of a paramagnetic contrast agent, usually a
gadolinium (Gd) chelate bolus [14].
Contrast-enhanced perfusion-weighted MR imaging
(PWI) can be performed in two ways. The first is called
T1-based perfusion and utilizes the shortening of the T1
relaxation time of tissues by the paramagnetic Gd-based
contrast agent. This “T1 effect” is proportional to the
amount of contrast media passing through the region under
investigation. To observe the changes in the T1 relaxation
time, a fast T1-w sequence has to be executed, and the
dynamic course of the changes in T1 times is evaluated.
T1-based PWI is applied to study the contrast uptake of
organs and tissues in the abdomen and thorax (e.g., breast,
heart, prostate), usually using a 3D spoiled gradient echo
sequence, since this approach allows the acquisition of
dynamic information within a breath-hold with good image
quality and spatial resolution. It is used to improve tumour
diagnosis, evaluate response to therapy, and to detect
residual or recurrent tumour. The second PWI method is
called T2*-based perfusion and exploits the influence of
paramagnetic contrast agent on the local magnetic field
which leads to a reduction of the T2* relaxation time in
surrounding tissue [14]. A very fast T2*-sensitive sequence
has to be performed to measure these changes in the T2*
relaxation time, i.e., EPI sequences are commonly applied.
During the passage of the contrast agent bolus, the MR
signal decreases due to the reduction of T2*, but the signal
recovers at least partially after the passage. The differences
in occurrence and magnitude of the signal changes are
evaluated via an arterial input function (AIF). T2*-based
PWI allows for imaging of flow at the capillary level. The
measurement of brain perfusion helps to differentiate
between acute stroke, hypoglycaemia, hyponatremia, sei-
zure, tumour or subdural hematoma. In acute stroke, for
instance, the difference between the diffusion abnormalities
measured with DWI and perfusion abnormalities measured
with PWI provides a measure of the ischemic penumbra or
the brain tissue at risk.
Diffusion-weighted MRI
Diffusion-weighted MRI (DWI) assesses the Brownian
motion of water molecules and provides information about
tissue structure and intra/extracellular space via the “appar-
ent diffusion coefficient” ADC [15]. DWI shows broad
clinical application in diagnosis of acute cerebral infarction,
characterization and therapy monitoring of tumours, and
differentiation of gliomas from brain abscesses or lympho-
mas [16]. A DWI sequence detects the signal attenuation
due to diffusion of water molecules. The essential param-
eters for the “diffusivity weighting” are the strength and
timing of the diffusion gradients and can be expressed with
the “b-factor”. Higher b-factors lead to stronger signal
drop-off in areas with higher diffusion. The observed signal
decay can be used to calculate the diffusion properties or
ADC.
Depending on the anatomical region, diffusion can occur
unrestricted and equal in magnitude in all spatial directions,
which is referred to as isotropic diffusion. However,
mobility of the water in biological tissue can show a
preferred direction governed by structures, e.g., restriction
of diffusion by myelinated sheets of nerve fibres, which is
referred to as anisotropic diffusion. The DWI method
provides information about the magnitude of water diffu-
sion but not about its direction.
Diffusion tensor MR imaging
Diffusion tensor MR imaging (DTI) enables the measure-
ment of anisotropic diffusion of water molecules in tissues
such as the white brain matter and provides insight into the
microstructure of tissues (Fig. 5 D) [17, 18]. DTI shows
application in clinical routine for preoperative planning of
brain tumour surgery to differentiate peritumoural oedema
from tumour border, to assess tumour rim into white-matter
tracts, and to visualize and localize the major white-matter
tracts (e.g., pyramidal tract; Fig. 5c) intraoperatively [19].
This strategy can help to avoid injuries to normal and/or
functionally important brain areas. Application of DWI
and DTI is more problematic in regions outside of the
brain, e.g., due to increased motion and susceptibility
artefacts. However, these methods may provide helpful
information regarding the nature and extent of cancer in
several organs, which is currently a field of clinical
investigations.
Magnetic resonance spectroscopy
MR-based spectroscopy (MRS) is a noninvasive diagnostic
tool that allows for the detection of amount and spatial
distribution of various molecular compounds, which are
involved in the metabolism of pathologic and healthy
tissue. In proton MRS (1H-MRS), the most important
metabolites are creatine (Cr), choline (Cho), N-acetyl-
acetate (NAA), citrate (Cit), lactate (Lac) and lipids [20].
Unfortunately, no marker specific for cancer and detectable
via in vivo MRS exists today. However, one can detect
typical metabolic profiles in MRS spectra that provide an
indication for cancer [21]. Various studies have assessed the
potential of 1H-MRS to improve diagnosis and prognosis of
pathologies in the central nervous system, especially of
brain tumours (Fig. 5 B). In recent years, 1H-MRS has been
applied also for diagnosis of other common cancer types
such as prostate and breast carcinoma [22, 23].
3D 1H-MRS sequences with a spatial resolutions
comparable to that of PET [7] suffer from low signal-to-
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noise and have the drawback of long acquisition times. The
application of so-called parallel imaging techniques (e.g.,
SENSE) [24] is a strategy to overcome this problem.
However, 1H-MRS is very sensitive to susceptibility
artefacts, which excludes the use of this method in patients
with subcranial, frontobasal, temporal, etc. lesion locations
or in patients after surgery. Unfortunately, these problems
are more evident at higher magnetic field strength.
The sensitivity of 1H-MRS is in the range of millimolars.
Positron-emitting analogues of molecules, which are in-
volved in metabolic processes, can be detected with PET in
picomolar concentrations. A wide variety of PET tracers
tracers have been developed to target the transport and
metabolism of glucose (FDG) and amino acids (18F-
fluorothymidine or 18F-fluoroethyltyrosine; Fig. 5 E). On
the other hand, 1H-MRS may be performed with any modern
MRI system without the need for exogenous tracers, while
the availability of PET is still limited in part due to the
substantial infrastructure required for tracer production.
Whole-body tumour staging
Whole-body tumour staging utilizing MRI has now become
feasible due to several technical innovations: whole-body
coverage with RF surface coils (Fig. 2), multiple RF
receiver channels, extended and fast table translation. Prior
Fig. 5 Multi-modality imaging
of a 39-year-old female patient
with a glioblastoma multiforme
IV. (a) axial T2w MR with
manually segmented tumour
volume (orange), pyramidal
tract (blue) and volume of
BOLD activation based on foot
movement (green), (b)
segmented map of Cho/NAA
and a spectrum of the central
tumour with a Cho peak, (c)
coronal T1w MR fused with the
volumes from (a, d) colour-
coded coronal image of frac-
tional anisotropy (FA) as a result
of a DTI experiment (blue feet–
head, red left–right, green ante-
rior–posterior), and e sagittal
18F-FET PET fused with the
volumes from (a)
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to these innovations, MR has been limited to examination
of a single organ region, which fit within the homogeneous
FOV of the magnet. It is now possible to perform complete
TNM-staging using multiple pulse sequence 15–30 min,
depending on the exact protocol and image resolution
[3, 25].
To ensure the highest diagnostic accuracy, paramagnetic
contrast agents are used. The logistics of contrast admin-
istration for examination of multiple body regions is a
major consideration in the development of clinical proto-
cols. Here, the cumulative dose is limited, and dynamic
contrast diminishes after multiple injections due to contrast
uptake in the surrounding tissue. Figure 6 shows an
example of a state-of-the-art oncology staging protocol,
which enables the acquisition of dynamic contrast agent
uptake in the abdominal organs and the evaluation of
steady-state contrast enhancement of brain and other
lesions.
SNR/artefacts
Many practical imaging decisions are based on a compro-
mise between the SNR and the time available for image
acquisition, as the SNR increases with the square root of
acquisition time. SNR also increases approximately linearly
with the main magnetic field strength [26]. A higher SNR
translates into improved spatial resolution or reduced scan
times. Any modification of the MR environment, for
example, by adding PET components to the MR, must
avoid significant degradation of the SNR.
Anatomical Region Sequence Type Duration 
 
abdomen 1-w 2D spoiled GE 
T2-w 2D single-shot SE 
25 s (breathhold) 
25 s (breathhold) 
 
thorax  T1-w 2D spoiled GE 
T2-w 2D single-shot SE 
25 s (breathhold) 
25 s (breathhold) 
 
pelvis T1-w 2D spoiled GE 
T2-w 2D single-shot SE 
25 s (breathhold) 
25 s (breathhold) 
 
abdomen T1-w 3D spoiled GE with FS 
(pre-CA) 
22 s (breathhold) 
 
intravenous bolus injection of single dose 0.5M Gd CA (10ml for 50kg BW) 
abdomen T1-w 3D spoiled GE with FS 
(arterial CA phase) 
22 s (breathhold) 
 
abdomen T1-w 3D spoiled GE with FS 
(portal venous CA phase) 
22 s (breathhold) 
 
thorax T1-w 3D spoiled GE with FS 
(steady-state CA phase) 
22 s (breathhold) 
 
pelvis T1-w 3D spoiled GE with FS 
(steady-state CA phase) 
22 s (breathhold) 
 
upper legs T1-w 3D spoiled GE with FS 
(steady-state CA phase) 
22 s  
 
head T1-w 3D spoiled GE with FS 
(steady-state CA phase) 
22 s 
 
abdomen T1-w 3D spoiled GE with FS 
(late venous CA phase) 
22 s (breathhold) 
 
 ca. 6 min. total imaging time 





Fig. 6 Clinical examination protocol for whole-body MRI oncologic
staging. Contrast logistics place constraints on the timing and order of
particular imaging regions, leading to multiple table movements
between imaging regions. These constraints may be in conflict with
the needs of sequential PET imaging. (w weighted, GE gradient echo,
SE spin echo, FS fat saturation, CA contrast agent, BW body weight)
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Several other sources of image quality degradation must
also be avoided [27, 28]. Due to the switching gradient
magnetic fields and also due to the high-frequency RF
fields, currents can be induced in electrically conducting
structures, which can lead to signal dropouts and other
artefacts. In addition to having low conductivity, all
materials in the imaging FOV should also provide a good
magnetic susceptibility (χ) match to either air (χ≈0) or to
the human tissue that is slightly diamagnetic (χ≈−9×10−6).
Metallic materials which have a different susceptibility will
cause distortion in the homogeneity of the main magnetic
field, leading to geometric distortion of the image due to
false mapping of signal. The accompanying intra-voxel
phase dispersion may lead to signal dropout (Fig. 7 A).
Furthermore, a MR system is a very sensitive radio
receiver tuned to a frequency band centred around 64 MHz
at 1.5T and 128 MHz at 3T (for hydrogen protons and less
for other nuclei). Any electronic noise at the reception
frequency will cause banding artefacts in the images
(Fig. 7b), or elevated noise levels. Common sources of
such noise are any active electronics, and all electronics
must be properly shielded to avoid interference.
MR imaging is also susceptible to some artefacts which
may hamper proper co-registration of images with an
independent imaging modality such as PET. These
imperfections may be of particular consequence for
attenuation correction algorithms based on the MR data,
which rely on proper overlay of the complementary image
sets.
First, since many MR imaging sequences are rather
slow compared to physiological processes, cardiac and
breathing motion often contaminate the images (Fig. 7d),
which is a familiar problem from PET/CT imaging. In
addition, signal localization in MR imaging is achieved by
the application of ideally linear gradients in the magnetic
field. However, due to hardware limitations and the
potential of peripheral nerve stimulation during very fast
imaging, a certain amount of nonlinearity is acceptable in
the periphery of the nominal imaging FOV. As a conse-
quence, the signal is mapped to the incorrect location in the
reconstructed image, up to several centimetres at the
periphery of large FOVs [29] (Fig. 7c). Although correction
algorithms are available, they are typically limited to in
plane correction, and they cannot account for extreme
nonlinearities.
Finally, it is common in MR imaging to undersample
the raw data space in order to save acquisition time.
Undersampling in the spacing of raw data lines in the
phase-encoding direction leads to fold-over artefacts if the
effective FOV is smaller than the object being imaged.
This strategy is followed when the imaging region is of
limited extent, such as in cardiac exams (Fig. 7e).
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Fig. 7 Characteristic image distortions in MR. (a) Susceptibility
artefact (arrow) from a metal fixation screw in the spine; (b) RF
artefact (arrows) from improper sealing of the door to the MR
examination room; (c) gradient nonlinearity leading to spatial
distortion in a 400×400 mm2 FOV (top); after software correction
(bottom). (d) abdominal respiratory motion artefacts in the anterior-
to-posterior phase-encoding direction; and (e) fold-over artefact
(arrows) in the left-to-right phase-encoding direction of a short-axis
cardiac view
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Obviously, MR-based attenuation correction based on
images suffering from fold-over distortions will be quite
challenging.
Discussion and outlook
MR imaging has experienced rapid growth since its
introduction into clinical routine in the 1980s. Much of
this growth is due to the enormous flexibility of the method
and the large variation in tissue contrasts that can be
achieved to reveal pathology and detailed structural and
biochemical information. The clinical synergies that can be
achieved by a multimodality approach [30] combining
simultaneous or quasi-simultaneous PET and MRI in
humans are still unknown, although first results from
animal studies are rather promising [32]. To achieve
maximum impact, the strengths and weaknesses of both
imaging techniques need to be considered and strategies
developed, which account for complementary imaging
properties. The following concerns come to mind:
(a) high-resolution MR images that complement PET
should be the least affected by a PET insert, in
particular in the brain, as very strong gradient inserts
(≥100 mT/m) may be used to compensate for
geometric distortions or susceptibility artefacts,
(b) functional MRI of the brain (i.e., BOLD fMRI,
perfusion, diffusion) using EPI or spiral imaging
would be very sensitive to SNR or CNR losses
caused, e.g., by PET inserts. This may be compensat-
ed, in part, by longer measurement times or higher
field strengths,
(c) the most serious problems are to be expected in whole-
body PET/MR at high field strengths. Limitations are
due to inherent MR problems such as reduced
homogeneity in large FOVs and dielectric losses,
leading to signal losses, which would be further
exacerbated by PET components that reduce SNR
and/or increase susceptibility differences,
(d) user-friendly 3D doctors, finally, integrated models
will need to be developed and tested in order to better
understand the origins of complex diseases.
Assuming these challenges can be addressed, the
question still remains, how a practical examination could
be performed on a combined PET/MR tomograph. Even if
the hardware enables simultaneous artefact-free data acqui-
sition for both modalities, would it make sense? Individual
MR sequences for imaging the head often last minutes. If
the longitudinal FOV of the PET is sufficient to cover the
brain, then several individual MR contrasts could be
acquired, while counts are continuously collected for
reconstruction of a single, low-noise PET dataset. For
imaging outside the brain with combined PET/MR, a
similar strategy to brain imaging might be pursued if the
area of interest is limited to a single organ.
For examinations requiring extended FOV coverage, on
the other hand, the examination logistics may not be as
straightforward. For most oncologic staging applications,
multiple longitudinal FOVs must be sampled. The
longitudinal FOV of most MR scanners is 40–50 cm,
exceeding typical PET FOVs by a factor of 2–3. Even if
the PET FOV can be extended to cover a larger extent,
the acquisition of MR contrast agent dynamics may force
movement between individual table positions every 20–
25 s. PET data sampling will have to be repeatedly
stopped and resumed when the table returns to the
appropriate position. Current PET/CT implementations
subdivide the problem into two sequential acquisitions:
first CT then PET. This will most likely not be possible in
PET/MR imaging, as there will be periods of “slow” MR
data acquisition where it would be inefficient not to
acquire PET counts.
Regardless of whether simultaneous PET/MR ultimately
makes its way into clinical routine, the efforts to integrate
these two technologies will surely expand our understand-
ing how to best exploit the complementary strengths of
these two powerful imaging modalities. The role of both
PET and MR in medical diagnostics, whether combined or
individually, will continue to expand.
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